These FTSE 100 stocks rocketed 20% in February. Can they keep going?

Royston Wild runs the rule over two FTSE 100 (INDEXFTSE: UKX) chargers.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Medicines mammoth Hikma Pharmaceuticals (LSE: HIK) continued its recovery from a shocking second half of 2016 in February, the stock advancing 18% during the course of the month.

The pharmaceuticals space has been a popular destination for share investors seeking safe havens, the broad global footprint of their operations — allied with the essential nature of their products — providing peace of mind as another year of political and economic uncertainty beckons.

Hikma’s last trading statement in November however, caused a fresh frenzy of selling activity as worse-than-expected volume growth of its Generics products forced it to warn that full-year group sales would come in at the lower end of expectations, at $2bn.

As a consequence, Hikma is expected to record another bottom-line decline in 2016 by City analysts — a 33% drop is currently anticipated.

Having said that, the huge potential of Hikma’s Generics business in the long term remains undimmed, and the firm expects revenues here alone to rise by a third in 2017 from last year’s levels thanks to expected product rollouts. But this is not the only cause for optimism as the massive investment made at its Injectables division is blasting demand higher.

The number crunchers expect these factors to deliver growth of 38% and 29% in 2017 and 2018 respectively. And while Hikma deals on a forward P/E rating of 20 times, sitting above the FTSE 100 average of 15 times, I reckon the healthcare giant’s solid growth outlook — in the near-term and beyond — warrants such a premium.

Plane crazy?

Plane-building powerhouse Rolls-Royce (LSE: RR) also enjoyed a stellar share price charge in February, the stock gaining 19% in value in an often-volatile period.

It saw an eye-watering £4.6bn pre-tax loss in 2016, it announced last month, the biggest in its history. As well as suffering a £4.4bn currency hedge-book hit due to sterling weakness, Rolls-Royce also swallowed a £671m penalty from UK, US and Brazilian regulators in order to draw a line under bribery allegations made in overseas markets.

However, investors breathed a sigh of relief as full-year results were not as bad as many had feared. After-market services revenues in the civil aerospace segment are showing signs of tentative improvement, for example. And Rolls-Royce’s modernisation programme is also moving ahead of schedule — indeed, savings last year of £60m beat the targeted range of £30m-£50m.

After three years of consecutive earnings dips, the City expects Rolls-Royce to get back into gear with a 7% rise in 2017, before returning to double-digit growth with a 17% advance in 2018.

But the engineer is clearly still loaded with risk, with subdued demand for wide-body aircraft hampering sales of Rolls-Royce’s power units, and capex reductions in the oil market still casting shadows over its Marine division. And some would argue Rolls-Royce is therefore unbefitting of an elevated forward P/E ratio of 24.4 times.

I reckon the company may struggle to add to February’s gains.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

It’s up 70%, but the experts expect the IAG share price to climb still further

Why didn't I buy when I was convinced the IAG share price was likely to soar? And is there still…

Read more »

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

2 UK stocks with recovering profit margins

This writer considers a pair of UK stocks with very different share price trajectories following the pandemic. Would he buy…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Will Trump’s tariffs squeeze this FTSE 100 giant’s profits?

Our writer looks at how the latest news around US tariffs might impact FTSE 100 company Diageo. Should he be…

Read more »

Investing Articles

Up 95%, is this FTSE winner the best high-yield star for me to buy now?

Do we have to choose between share price growth and high-yield dividends? In this case, over the past year, it…

Read more »

Asian Indian male white collar worker on wheelchair having video conference with his business partners
Investing Articles

2 dividend-paying FTSE shares that could benefit from the AI revolution

Our writer examines two dividend-paying FTSE shares and explains some of the opportunities and risks he sees in their exposure…

Read more »

Investing Articles

Up 140% and rocketing out of the FTSE 250! Is it too late for me to buy this red-hot stock?

Miniature war games hero Games Workshop has outgrown the FTSE 250 and is hammering at the door of the UK's…

Read more »

Investing Articles

If I invest £10,000 in Taylor Wimpey shares, how much passive income will I receive?

Taylor Wimpey shares have fallen and are now paying a huge dividend. How much might I receive by investing a…

Read more »

Index Funds text carved in stone background
Investing Articles

Why I choose to invest in individual stocks rather than an index fund

Our writer examines the differences between stock picking and investing in index funds and why he feels there’s more to…

Read more »